🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/08/2021 30,06 30,15 29,30 30,02 -0,10% 2,84% 297.200
02/08/2021 31,20 31,54 30,00 30,05 -4,33% 4,94% 459.900
30/07/2021 32,90 33,27 31,36 31,41 -4,73% 5,81% 308.400
29/07/2021 33,98 34,76 32,90 32,97 -2,71% 5,47% 352.600
28/07/2021 31,83 34,12 31,65 33,89 +7,01% 7,76% 412.100
27/07/2021 32,48 32,67 30,31 31,67 -3,06% 7,27% 415.700
26/07/2021 32,90 32,94 31,91 32,67 -0,55% 3,13% 271.400
23/07/2021 33,03 33,45 32,52 32,85 -0,48% 2,82% 304.300
22/07/2021 31,88 33,28 31,35 33,01 +4,07% 6,04% 608.900
21/07/2021 31,54 31,73 30,00 31,72 -0,91% 5,49% 663.000
20/07/2021 29,60 33,21 29,60 32,01 +8,03% 12,21% 1.200.900
19/07/2021 28,93 29,99 28,65 29,63 +0,54% 4,63% 547.500
16/07/2021 28,95 29,75 28,57 29,47 +3,11% 4,08% 502.700
15/07/2021 28,26 28,70 26,98 28,58 +0,04% 6,09% 835.300
14/07/2021 28,58 28,85 27,83 28,57 +0,60% 3,57% 1.010.200
13/07/2021 29,18 29,35 28,12 28,40 -3,17% 4,22% 680.200
12/07/2021 28,97 29,35 28,67 29,33 +0,89% 2,34% 366.300
09/07/2021 28,72 29,19 28,46 29,07 +1,11% 2,52% 726.900
08/07/2021 28,28 29,24 28,19 28,75 -0,79% 3,71% 777.500
07/07/2021 27,95 29,29 27,80 28,98 +3,57% 5,33% 748.200
06/07/2021 27,42 28,15 26,87 27,98 +2,45% 4,69% 749.500
02/07/2021 27,60 27,62 26,71 27,31 -0,80% 3,30% 556.200
01/07/2021 27,72 27,72 26,78 27,53 +0,25% 3,39% 884.700
30/06/2021 27,23 28,05 26,84 27,46 +0,70% 4,44% 548.000
29/06/2021 28,86 28,89 27,01 27,27 -6,10% 6,51% 644.400
28/06/2021 28,90 29,43 28,40 29,04 +0,73% 3,56% 862.300
25/06/2021 26,55 28,83 26,06 28,83 +6,70% 10,43% 3.529.400
24/06/2021 27,65 28,40 26,16 27,02 +15,47% 8,10% 4.184.700
23/06/2021 22,63 23,91 22,63 23,40 +2,86% 5,66% 1.183.700
22/06/2021 23,14 23,49 22,62 22,75 -3,23% 3,76% 381.200